Innovations and Emerging Trends in Prostate Cancer Management: A Literature Review DOI Open Access

Nazeer Ibraheem,

Momen Abdelglil,

Andrew Wanees

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

Prostate cancer (PC) is considered the second most diagnosed in men worldwide. It remains a leading cause of cancer-related death. Recently, many modalities have been discovered and used diagnosis management PC, with incorporation treatment options such as hormonal therapy, chemotherapy, targeted therapies, immunotherapy, precision medicine. Robotics artificial intelligence (AI) further modified PCs, improving accuracy disease progression. This comprehensive review offers an in-depth exploration historical treatments, evaluation current therapeutic techniques, discussion use robotic surgery AI, examination ongoing clinical trials emerging procedures. Additionally, this also covers challenges. By inspecting these aspects, may provide valuable information regarding future research practice directions PC treatment, contributing to thorough understanding complex context management.

Language: Английский

Mulberrin suppresses gastric cancer progression and enhances chemosensitivity to oxaliplatin through HSP90AA1/PI3K/AKT axis DOI

Yongsen Li,

Mengyao Dong,

Hong Qin

et al.

Phytomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 156441 - 156441

Published: Jan. 1, 2025

Language: Английский

Citations

2
HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells DOI Creative Commons
Masanobu Tsubaki,

Taira Matsuo,

Rie Komori

et al.

Future Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 27, 2025

Abstract Background Chronic myeloid leukemia is associated with a more favorable prognosis following treatment BCR::ABL1 tyrosine kinase inhibitors (TKIs). Nonetheless, about 40% of affected individuals CML display resistance or intolerance towards TKIs. Heat shock protein 90 (HSP90) functions as molecular chaperone and known for its overexpression in various types cancer, thereby HSP90 potential candidate the TKI-resistant -sensitive CML. In present study, we aimed to investigate whether promote cell death imatinib-resistant cells. Results KW-2478 NVP-AUY922, which are inhibitors, promoted both Imatinib-resistant cells showed greater sensitivity comparison imatinib-sensitive inhibited activation Akt, extracellular regulated 1/2, c-Jun N-terminal 1/2 by promoting Met degradation. Conclusion These findings indicate inhibition such NVP-AUY922 candidates therapy.

Language: Английский

Citations

0
Active Iron‐Drug Nanocomplexes Improve Photodynamic and Photothermal Cancer Therapy by Mitigating Tumor Hypoxia and Counteracting Tumor Heat Resistance DOI Creative Commons
Yue-Ping Yin,

Ka Hong Wong,

Liewei Wen

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 23, 2025

Abstract Photodynamic therapy (PDT) and photothermal (PTT) offer the advantages of precise temporal spatial selectivity in cancer treatment, minimizing damage to normal cells while effectively eliminating tumor cells. However, therapeutic efficacy phototherapy is always hindered by challenges such as hypoxia heat resistance. Herein, a pH‐responsive metal‐drug nanocomplex (denoted PAFH) comprising hypericin (HYP), apigenin (APG), polyvinylpyrrolidone (PVP), Fe 3+ developed enhance PDT PTT. The PAFH exhibits properties under 808 nm laser irradiation, which can disassociate response acidic microenvironment temperature increase induced PTT, thereby eventually triggering on‐site release APG HYP. released inhibits synthesis shock protein HSP‐90, facilitating PAFH‐mediated PTT kill at mild temperature. Additionally, alleviates then regulates expression hypoxia‐inducible factor HIF‐1𝛼, increasing cellular oxygen levels produce singlet for enhanced HYP‐mediated inhibiting metastasis. Ultimately, this sophisticated nanosystem represents an advanced strategy promote mitigating counteracting resistance, significantly improving therapy.

Language: Английский

Citations

0
Recent progress and structural insights of potential Hsp90 inhibitors as anticancer agents DOI

Aastha Singh,

Satyabrata Maity,

Priya Devi

et al.

Molecular Diversity, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Language: Английский

Citations

0
Targeting Proteostasis Pathways for Cancer Therapy DOI Creative Commons
Xiaofeng Dai,

Ruohan Lyu,

Guanqun Ge

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101287 - 101287

Published: March 1, 2025

Language: Английский

Citations

0
The Hsp90β Isoform: An Attractive Target for Drug Development DOI Creative Commons
Subhabrata Chaudhury, Terin D’Amico, Brian S. J. Blagg

et al.

Medicinal Research Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

ABSTRACT The beta isoform of 90 kDa heat shock protein (Hsp90β) plays a critical role in maintaining cellular proteostasis by assisting the folding and refolding proteins, which is essential for both normal function stress response. It constitutively expressed mammalian cells, differentiating it from inducible Hsp90α isoform. Hsp90β's involvement diverse processes, such as signal transduction, cell cycle control, apoptosis, underscores its significant various diseases, including cancer neurodegenerative disorders. isoform‐specific functions Hsp90β interaction with unique client proteins make promising target therapeutic intervention, particularly development selective inhibitors that avoid adverse effects observed pan‐Hsp90 inhibitors. This review delves into structural functional intricacies Hsp90β, disease, potential drug development.

Language: Английский

Citations

0
Innovations and Emerging Trends in Prostate Cancer Management: A Literature Review DOI Open Access

Nazeer Ibraheem,

Momen Abdelglil,

Andrew Wanees

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

Prostate cancer (PC) is considered the second most diagnosed in men worldwide. It remains a leading cause of cancer-related death. Recently, many modalities have been discovered and used diagnosis management PC, with incorporation treatment options such as hormonal therapy, chemotherapy, targeted therapies, immunotherapy, precision medicine. Robotics artificial intelligence (AI) further modified PCs, improving accuracy disease progression. This comprehensive review offers an in-depth exploration historical treatments, evaluation current therapeutic techniques, discussion use robotic surgery AI, examination ongoing clinical trials emerging procedures. Additionally, this also covers challenges. By inspecting these aspects, may provide valuable information regarding future research practice directions PC treatment, contributing to thorough understanding complex context management.

Language: Английский

Citations

0